CD274 and neoplasm: Median duration of response by BICR with nivolumab plus ipilimumab was 11.8 months (95% CI 6.8–18.0) versus 5.7 months (95% CI 4.4–8.7) with chemotherapy in patients with tumor cell PD‐L1 expression ≥1% (Figure 2E and Table 2) and was 11.1 months (95% CI 7.1–14.3) and 7.1 months (95% CI 5.7–8.2) in the overall population (Figure 2F and Table 2).